-
1
Momelotinib is an FDA-approved JAK inhibitor for treating anemic patients with high/intermediate risk myelofibrosis as of September 15, 2023.
-
2
The drug targets JAK1, JAK2, JAK3, TYK2, and ACVR1, aiming to alleviate symptoms like splenomegaly and anemia in myelofibrosis patients.
-
3
In clinical trials, momelotinib showed a 57% clinical improvement rate and a 45% anemia response among treated patients.
-
4
Adverse events associated with momelotinib included thrombocytopenia, peripheral neuropathy, and gastrointestinal symptoms, with varying severity.
-
5
Momelotinib's unique erythropoietic effect distinguishes it from other JAK inhibitors, which primarily manage splenomegaly and constitutional symptoms.
